L. Denis
4 Papers
6 Citations
L. Denis is an academic researcher. The author has contributed to research in topics: Interquartile range & Granulomatosis with polyangiitis. The author has an hindex of 2, co-authored 4 publications.
Chat about Author
Papers
Lymphocyte Immunophenotyping and CD4/CD8 Ratio in Cerebrospinal Fluid for the Diagnosis of Sarcoidosis-related Uveitis.
Romain Paule,L. Denis,Nicolas Chapuis,Julien Rohmer,Jérôme Hadjadj,Jonathan London,Anthony Chauvin,Clemence Bonnet,Luc Mouthon,Claire Le Jeunne,Dominique Monnet,Philippe Blanche,Antoine P. Brézin,Benjamin Terrier +13 more
TL;DR: Determination of CD4/CD8 ratio in CSF can be useful for diagnosis work-up since a CD4 / CD8 ratio >3.23 inCSF is associated with ocular sarcoidosis.
6
Sat0221 off-label use of biological therapies in relapsing and/or refractory polyarteritis nodosa
Alice Canzian,Omer Karadag,A. Contis,François Maurier,Silvia Sartorelli,L. Denis,Sébastien Sanges,Claire de Moreuil,Cécile-Audrey Durel,Stéphane Durupt,Marie Jachiet,D. Rouzaud,Carlo Salvarani,Franco Schiavon,Lorenzo Dagna,Fabrice Bonnet,David Jayne,Loïc Guillevin,Benjamin Terrier +18 more
TL;DR: It is suggested that TNF-alpha blockers and TCZ may achieve higher rates of remission and GC-sparing in relapsing and/or refractory PAN than other biologics.
Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis With Polyangiitis: Data From a European Collaborative Study.
Alice Canzian,Nils Venhoff,Maria Letizia Urban,Silvia Sartorelli,Anne-Marie Ruppert,Matthieu Groh,Nicolas Girszyn,Camille Taillé,François Maurier,Vincent Cottin,Claire de Moreuil,Vincent Germain,Maxime Samson,Marie Jachiet,L. Denis,Virginie Rieu,Perrine Smets,Grégory Pugnet,Alban Deroux,Cécile-Audrey Durel,Achille Aouba,Pascal Cathébras,Christophe Deligny,Stanislas Faguer,H. Gil,Bertrand Godeau,François Lifermann,Sophie Phin-Huynh,Marc Ruivard,Philippe Bonniaud,Xavier Puéchal,Jean-Emmanuel Kahn,Jens Thiel,Lorenzo Dagna,Loïc Guillevin,Augusto Vaglio,Giacomo Emmi,Benjamin Terrier +37 more
TL;DR: To describe the efficacy and safety of biologics for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA).